CVS Health raised its annual profit forecast following a strong Q2 driven by profitable drug mixes and insurance bonuses, while expanding access to weight-loss treatments like Wegovy and Zepbound.
CVS Health's Caremark settled with the FTC to curb rebate practices and count TrumpRx purchases toward deductibles. The deal targets billions in drug price savings and addresses anticompetitive behavi
CVS Health raised its 2026 profit forecast citing improved medical cost controls and a more profitable drug mix at Caremark. Shares rose 4% as the company beat quarterly earnings estimates despite reg
ChemBrief